The Permanent vs. the Reversible
For the past decade, gene editing has been synonymous with permanence. CRISPR-Cas9, base editing, and prime editing all share one fundamental trait: they alter the DNA itself, rewriting the genome in a way that persists through every cell division for the rest of a patient's life. That permanence is both the greatest strength and the greatest liability of DNA editing. If the edit is correct, the patient may be cured forever. If something goes wrong, there is no undo button.
RNA editing offers a fundamentally different proposition. Rather than changing the blueprint, it changes the message. RNA is the transient intermediary that carries instructions from DNA to the protein-making machinery of the cell. Edit the RNA, and you change the protein that gets made, but you leave the underlying DNA untouched. When the edited RNA molecules degrade, as all RNA molecules eventually do, the effect fades. The cell goes back to reading the original DNA and making the original message.
This distinction, permanence versus reversibility, is shaping the next decade of genetic medicine. The question is no longer just "can we fix this gene?" but "should we fix it permanently, or is a reversible correction safer, more practical, or more appropriate for this particular disease?"
DNA Editing: The Permanent Rewrite
DNA editing technologies aim to correct the genome itself. The three major approaches differ in their mechanisms but share the goal of making lasting changes.
CRISPR-Cas9: Cut and Repair
The original CRISPR-Cas9 system, adapted from a bacterial immune defense, works by cutting both strands of the DNA double helix at a targeted location. The cell's own repair machinery then fixes the break. Researchers can exploit this process to disable a gene (by introducing errors during repair) or insert new DNA sequences (by providing a template for the cell to copy).
CRISPR-Cas9 is powerful but imprecise. Double-strand breaks trigger unpredictable repair outcomes, including insertions, deletions, and chromosomal rearrangements. Off-target cuts at unintended genomic locations remain a concern, particularly for therapeutic applications where millions or billions of cells are edited simultaneously.
Base Editing: Chemical Letter Swaps
Developed by David Liu's lab at the Broad Institute, base editors avoid cutting DNA entirely. Instead, they chemically convert one DNA letter into another at a precise location. Cytosine base editors (CBEs) change C-G pairs to T-A pairs, while adenine base editors (ABEs) change A-T pairs to G-C pairs. Together they can address roughly 60% of known disease-causing point mutations.
Base editing is cleaner than CRISPR-Cas9 because there is no double-strand break, but it is limited to specific single-letter swaps and can sometimes cause unintended edits at nearby bases (bystander editing).
Prime Editing: Search and Replace
Prime editing, also developed in Liu's lab, uses a modified Cas9 protein fused to a reverse transcriptase enzyme. It can make all 12 possible single-letter changes, plus small insertions and deletions, without cutting both DNA strands. A "prime editing guide RNA" (pegRNA) carries both the targeting information and the template for the desired edit.
Prime editing is the most versatile DNA editing tool, but its efficiency remains lower than CRISPR-Cas9 or base editing in many cell types, and delivering the large prime editor protein into cells poses challenges.
The Common Thread
All three DNA editing approaches produce permanent changes. Once a patient's genome is altered, the edit is inherited by every daughter cell. For diseases caused by a single well-understood mutation, this permanence is ideal. But it also means that any mistakes, off-target edits, unintended chromosomal changes, or unforeseen biological consequences, are equally permanent.
RNA Editing: The Reversible Alternative
RNA editing takes an entirely different approach. Instead of modifying the genome, it modifies the messenger RNA (mRNA) transcripts that carry genetic instructions from DNA to the cell's protein factories. Because RNA is naturally short-lived (most mRNA molecules are degraded within hours to days), any edits to RNA are inherently temporary.
How ADAR-Based RNA Editing Works
The most advanced form of therapeutic RNA editing exploits a family of enzymes called ADARs (Adenosine Deaminases Acting on RNA). ADAR enzymes are naturally present in human cells and perform a specific chemical reaction: they convert adenosine (A) to inosine (I) in double-stranded RNA. The cell's translation machinery reads inosine as guanosine (G), so the net effect is an A-to-G change in the RNA message.
This is the same type of change that adenine base editors make in DNA, but it happens at the RNA level and is completely reversible.
Therapeutic RNA editing works by delivering a short synthetic guide RNA (often called an ADAR-recruiting oligonucleotide, or ARO) that binds to the target mRNA and creates a double-stranded RNA structure around the site of the disease-causing mutation. This double-stranded structure recruits the cell's own ADAR enzymes to the target site, where they perform the A-to-I edit. No foreign protein needs to be delivered to the cell. The guide RNA hijacks the cell's existing editing machinery.
Beyond A-to-I: Expanding the RNA Editing Toolkit
While ADAR-based A-to-I editing is the most clinically advanced form of RNA editing, researchers are working to expand the toolkit. ADAR enzymes can also be engineered to perform C-to-U edits (cytidine deamination), and entirely new RNA editing systems are being developed that could enable a broader range of changes.
Some approaches use engineered ADAR proteins delivered via mRNA or AAV vectors, rather than relying on endogenous ADAR recruitment. These offer greater flexibility but face the same delivery challenges as protein-based DNA editors.
Clinical Programs: RNA Editing Enters the Clinic
Several companies are advancing RNA editing therapies toward and through clinical trials, establishing proof of concept for this approach in human patients.
Wave Life Sciences: WVE-006 for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences is the furthest along in clinical development of RNA editing therapeutics. Their lead program, WVE-006, targets alpha-1 antitrypsin deficiency (AATD), a genetic condition that affects approximately 1 in 2,500 people of European descent. AATD is caused by a single point mutation (the "Z mutation," a G-to-A change in the SERPINA1 gene) that causes the alpha-1 antitrypsin (AAT) protein to misfold. Misfolded AAT accumulates in the liver, causing liver damage, while the shortage of functional AAT in the lungs leads to progressive emphysema.
WVE-006 is an ADAR-recruiting oligonucleotide, a short chemically modified RNA molecule that, when taken up by liver cells, binds to the SERPINA1 mRNA near the Z mutation site and recruits endogenous ADAR1 to convert the mutant A back to the wild-type G (read as G via the A-to-I change). This restores the normal AAT protein sequence, allowing the protein to fold correctly.
In Phase 1b clinical trial data reported in 2025, WVE-006 demonstrated dose-dependent increases in functional AAT protein levels in the blood of patients with AATD. The drug was administered subcutaneously (a simple injection under the skin) and was generally well tolerated. Notably, WVE-006 achieved RNA editing efficiencies of up to 50% or more at the target site in liver biopsies, translating to meaningful increases in circulating functional AAT.
The implications of the Wave program extend beyond AATD. WVE-006 validates the entire concept of endogenous ADAR recruitment as a therapeutic strategy. It demonstrates that a simple synthetic oligonucleotide, without any viral vector or foreign protein, can redirect the cell's own enzymes to correct a disease-causing mutation at the RNA level.
Wave's proprietary PN backbone chemistry, which enhances the stability, potency, and specificity of their oligonucleotides, is a key enabling technology. The company is also advancing RNA editing programs for other liver-expressed targets, and exploring delivery to the central nervous system.
HuidaGene: RNA Editing for MECP2 and Neurological Conditions
HuidaGene Therapeutics, a Shanghai-based biotech company, is pioneering RNA editing approaches for neurological diseases. Their most notable program targets MECP2-related disorders, including Rett syndrome.
Rett syndrome is a severe neurodevelopmental condition caused by mutations in the MECP2 gene on the X chromosome. It primarily affects girls and leads to progressive loss of motor and language skills, seizures, and breathing irregularities. MECP2 is a particularly challenging therapeutic target because the protein's expression level is critical: too little MECP2 causes Rett syndrome, but too much causes MECP2 duplication syndrome, an equally devastating condition. This dosage sensitivity makes permanent gene therapy approaches risky, as it is difficult to ensure that the right amount of MECP2 protein is produced in every cell.
RNA editing offers an elegant solution to the dosage problem. By correcting specific disease-causing mutations at the RNA level, the therapy preserves the cell's natural regulatory control over MECP2 expression. The corrected RNA is transcribed from the native gene locus, under the control of the native promoter and regulatory elements, so the amount of protein produced remains within physiological limits. If the editing efficiency is less than 100%, some mutant RNA molecules will still produce non-functional protein, but the corrected molecules will produce normal MECP2 at naturally regulated levels.
HuidaGene uses an engineered ADAR-based system delivered via adeno-associated virus (AAV) vectors to the central nervous system. Their preclinical data in mouse models of Rett syndrome have shown correction of MECP2 mutations, restoration of MECP2 protein levels, and improvement in behavioral and neurological phenotypes. The company has been advancing this program toward clinical trials.
The MECP2 program highlights a scenario where RNA editing may be fundamentally superior to DNA editing: diseases where gene dosage is critical and where permanent overexpression or underexpression could be as harmful as the original mutation.
Advantages of Reversibility
The reversible nature of RNA editing confers several practical and safety advantages over permanent DNA modification.
Safety and Risk Management
The most obvious advantage is the ability to stop. If an RNA editing therapy causes unexpected side effects, the treatment can simply be discontinued. Within days to weeks, as the guide RNA molecules are degraded and the edited RNA transcripts turn over, the effect dissipates entirely. The patient's cells return to their pre-treatment state. With DNA editing, there is no such off-ramp. An unintended permanent edit to the genome cannot be easily reversed.
This safety profile is particularly important in early clinical development, when the full range of a therapy's effects may not be known. RNA editing allows clinicians to start with low doses and titrate upward, adjusting the level of editing to balance efficacy and tolerability, much like dosing a conventional drug.
Tunable Dosing
RNA editing therapies can be dosed in a way that produces a specific level of protein correction. Because the editing effect depends on the concentration of guide RNA in the cell, and because that concentration can be controlled by the dose and frequency of administration, clinicians can adjust the therapeutic effect over time. This is impossible with one-and-done DNA editing, which produces a fixed level of correction determined at the time of treatment.
For diseases where the optimal level of protein correction may vary between patients or change over time (due to disease progression, aging, or other factors), tunable dosing is a significant advantage.
Preservation of Natural Regulation
As illustrated by the MECP2 example, RNA editing preserves the cell's native regulatory machinery. The edited RNA is still produced from the natural gene, under the control of natural promoters, enhancers, and regulatory elements. The cell retains the ability to control how much mRNA is made, when it is made, and in which cell types. DNA editing can disrupt these regulatory elements, and gene replacement therapies (which add an entirely new copy of a gene) typically bypass natural regulation altogether.
Reduced Immunogenicity
Many RNA editing approaches, particularly those based on synthetic oligonucleotides like Wave's AROs, do not require delivery of foreign proteins to the cell. This reduces the risk of immune responses that can limit the effectiveness of protein-based therapies (including Cas9-based DNA editing) and cause adverse events. The ADAR enzymes that perform the editing are the patient's own proteins, and the guide RNA molecules are chemically modified to avoid triggering innate immune sensors.
Applicability Across Mutations
While current ADAR-based editing is limited to A-to-G changes at the RNA level, many disease-causing mutations are G-to-A transitions at the DNA level (which produce the complementary A at the RNA level). This single edit type is relevant to a surprising number of genetic diseases. As the RNA editing toolkit expands to include C-to-U changes and other modifications, the range of treatable mutations will grow substantially.
Disadvantages of RNA Editing
Reversibility is not always an advantage, and RNA editing has genuine limitations that make it unsuitable for some applications.
Requires Repeated Dosing
Because the editing effect is temporary, RNA editing therapies must be administered repeatedly, potentially for the patient's entire lifetime. For subcutaneous injections administered every few weeks or months (as with WVE-006), this is manageable but represents a significant ongoing commitment. For approaches that require AAV delivery to the brain or other difficult-to-access organs, repeated dosing may not be practical due to immune responses to the viral vector.
The need for chronic treatment also means chronic cost, which raises questions about long-term affordability and access. A one-time DNA editing cure, even if expensive upfront, may be more cost-effective over a patient's lifetime than decades of repeated RNA editing treatments.
Limited Edit Types
Current clinical-stage RNA editing is limited to A-to-I (read as A-to-G) changes. This covers many but not all disease-causing mutations. DNA editing technologies, particularly prime editing, can make a much wider range of changes including all 12 single-letter transitions and transversions, plus insertions and deletions.
Efficiency Constraints
RNA editing must contend with the constant turnover of RNA molecules. To maintain a therapeutic level of correction, the guide RNA must continuously recruit ADAR enzymes to newly synthesized mRNA transcripts. If editing efficiency is only 30-50% (as seen in some current clinical data), a significant fraction of the disease-causing protein may still be produced. For gain-of-function diseases where the mutant protein actively causes harm, incomplete editing may not be sufficient.
Delivery Challenges for Some Organs
Synthetic oligonucleotides naturally accumulate in the liver after subcutaneous injection, making liver diseases the most accessible targets. Reaching other organs, particularly the brain, heart, muscle, and kidneys, requires specialized delivery technologies that are still in development. DNA editing faces similar delivery challenges, but the one-time nature of the treatment means the delivery problem only needs to be solved once.
When DNA Editing Is the Better Choice
Permanent DNA editing remains the superior approach in several scenarios:
One-and-done cures for severe monogenic diseases. For conditions like sickle cell disease or beta-thalassemia, where a single well-characterized mutation causes the disease and the affected cells (blood stem cells) can be edited outside the body and transplanted back, permanent DNA editing offers the prospect of a lifetime cure from a single treatment. The FDA-approved CRISPR therapy Casgevy for sickle cell disease exemplifies this approach.
Diseases where lifelong re-dosing is impractical. If the target organ is difficult to reach repeatedly (such as the brain or retina), a one-time permanent edit may be the only viable option. Repeated intrathecal injections or intravitreal injections, while possible, carry cumulative risks and significant burden.
Situations requiring large genetic changes. For diseases that require inserting a large gene, deleting a significant genomic region, or making complex rearrangements, DNA editing is the only option. RNA editing can change individual bases but cannot restructure the genome.
Gene knockouts. When the therapeutic goal is to permanently disable a harmful gene (as in CRISPR-based approaches to lower PCSK9 for cholesterol reduction), permanent disruption of the DNA is more appropriate than temporary RNA-level suppression, which would require indefinite treatment.
When RNA Editing Is the Better Choice
RNA editing has clear advantages in other scenarios:
Dosage-sensitive genes. As with MECP2, some genes must be expressed at precisely the right level. RNA editing preserves natural regulation and avoids the risk of over- or under-correction inherent in DNA editing or gene replacement.
Chronic conditions in accessible organs. For liver diseases like AATD, where the liver naturally takes up oligonucleotides and the treatment can be delivered by simple subcutaneous injection on a manageable schedule, RNA editing offers a favorable balance of efficacy, safety, and convenience.
Early clinical development and uncertain biology. When the long-term consequences of correcting a particular mutation are unknown, the ability to stop treatment and reverse the effect provides an important safety margin that permanent DNA editing cannot offer.
Pediatric applications where growth matters. In growing children, cells are dividing rapidly. A permanent DNA edit made in a fraction of liver cells may be diluted as the liver grows, potentially requiring re-treatment anyway. RNA editing, dosed at regular intervals, can be adjusted as the child grows.
Conditions where partial correction is sufficient. For many loss-of-function diseases, restoring even a modest percentage of normal protein function can have significant clinical benefit. RNA editing's current efficiency levels (30-60% at target sites) may be entirely adequate.
Head-to-Head Comparison
| Feature | DNA Editing (CRISPR/Base/Prime) | RNA Editing (ADAR-Based) |
|---|---|---|
| Target | Genomic DNA | Messenger RNA |
| Duration of effect | Permanent | Temporary (days to weeks) |
| Dosing | One-time (ideally) | Repeated (chronic) |
| Reversibility | No | Yes |
| Edit types available | All base changes, insertions, deletions | Primarily A-to-G (expanding) |
| Delivery requirements | Viral vectors or LNPs (often one-time) | Oligonucleotides (subcutaneous) or AAV |
| Foreign protein required | Yes (Cas9, base editor, or prime editor) | No (uses endogenous ADAR) for ARO approaches |
| Risk of permanent off-target edits | Yes | No (off-targets are also temporary) |
| Natural gene regulation preserved | Variable (can be disrupted) | Yes |
| Dosage tunability | Limited (fixed at time of treatment) | High (adjustable with dose/frequency) |
| Cost structure | High upfront, potentially curative | Lower per dose, chronic cost |
| Most advanced clinical example | Casgevy (approved, sickle cell) | WVE-006 (Phase 1b, AATD) |
| Best suited for | Severe monogenic diseases, gene knockouts | Dosage-sensitive genes, chronic conditions, safety-first applications |
The Future: Convergence, Not Competition
The framing of RNA editing "versus" DNA editing is useful for understanding the technologies, but the future of genetic medicine is likely to involve both approaches working in complementary roles. Several trends point toward convergence:
RNA editing as a stepping stone to DNA editing. Clinicians may use RNA editing first to validate that correcting a particular mutation produces the expected therapeutic benefit and is well tolerated, then offer patients the option of a permanent DNA edit once the safety profile is established. This "try before you buy" approach could dramatically reduce the risk of permanent gene editing therapies.
Combination therapies. Some diseases may benefit from permanent correction of one mutation at the DNA level combined with tunable RNA editing of another gene to optimize the therapeutic outcome. For example, a patient might receive a one-time DNA edit to correct the primary disease-causing mutation and ongoing RNA editing to modulate a modifier gene.
Platform convergence. The delivery technologies being developed for RNA editing (particularly lipid nanoparticles and chemically modified oligonucleotides) are also advancing delivery for DNA editors. Improvements in one field accelerate the other.
Expanding RNA editing capabilities. As RNA editing expands beyond A-to-G changes to include C-to-U edits and potentially other modifications, the range of diseases addressable by reversible editing will grow, giving clinicians more choices about whether permanence or reversibility is appropriate for each patient.
Regulatory evolution. Regulatory agencies are developing frameworks for both permanent and reversible genetic therapies. As more clinical data accumulates, clearer guidelines will emerge about which approach is preferred for which types of conditions, likely recognizing that one size does not fit all.
The underlying biological insight is straightforward: the central dogma of molecular biology, DNA to RNA to protein, offers two intervention points. Editing DNA changes the source code permanently. Editing RNA changes the running program temporarily. Both are valid therapeutic strategies, and the best choice depends on the disease, the patient, and the clinical context.
For patients and clinicians, the emergence of RNA editing as a viable therapeutic approach means more options, more flexibility, and, ultimately, safer paths to treating genetic disease. The permanent cure will remain the gold standard for some conditions. But for many others, the ability to edit, adjust, and if necessary, stop, may prove to be the wiser course.
Sources
- Wave Life Sciences. "WVE-006 Phase 1b Clinical Trial Data for Alpha-1 Antitrypsin Deficiency." Wave Life Sciences Investor Presentations, 2025.
- Merkle, T., et al. "Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides." Nature Biotechnology, 37(2), 133-138, 2019.
- Qu, L., et al. "Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs." Nature Biotechnology, 37(9), 1059-1069, 2019.
- Yi, Z., et al. "Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo." Nature Biotechnology, 40, 946-955, 2022.
- Komor, A.C., et al. "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage." Nature, 533(7603), 420-424, 2016.
- Anzalone, A.V., et al. "Search-and-replace genome editing without double-strand breaks or donor DNA." Nature, 576(7785), 149-157, 2019.
- Fry, L.E., et al. "RNA editing as a therapeutic approach for retinal gene therapy requiring repeat administration." International Journal of Molecular Sciences, 21(3), 777, 2020.
- HuidaGene Therapeutics. "ADAR-based RNA Editing for Neurological Diseases." Company Pipeline Overview, 2025.
- Katrekar, D., et al. "In vivo RNA editing of point mutations via RNA-guided adenosine deaminases." Nature Methods, 16(3), 239-242, 2019.
- U.S. Food and Drug Administration. "FDA Approves First Gene Therapies to Treat Sickle Cell Disease." FDA News Release, December 2023.
